Journal of drugs in dermatology : JDD · 2025
A Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Swenson Kirsten, Graber Emmy
Аннотация
BACKGROUND: Periorificial dermatitis (POD) is a facial skin rash often found in the oral commissures and nasolabial folds, and around the eyes. Treatment options include topical metronidazole and azelaic acid, and oral tetracycline-class antibiotics. While the broad-spectrum antibiotics are efficacious, they can lead to adverse gastro-intestinal (GI) symptoms, negatively impact gut flora, and lead to antibiotic resistance. Narrow-spectrum tetracyclines, such as sarecycline, have a low potential for promoting bacterial resistance and GI issues.
OBJECTIVE: The main objective of this study is to demonstrate sarecycline’s efficacy and safety in treating POD. It was hypothesized that subjects with POD given a 4-week course of sarecycline would have improvement in their POD and tolerate the medication well.
METHODS: This was a single-center, prospective, pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for the treatment of POD with once-daily dosing over 4 consecutive weeks. Subjects were evaluated using the PODSI score at weeks 0, 2, and 4.
RESULTS: All 9 subjects who completed the study had shown improvement in POD with no reported drug-related adverse events. All subjects were female, and the mean age was 41 years old.
CONCLUSION: Sarecycline may be an appropriate novel treatment option for POD and should be explored further in a larger population study capturing this data. Furthermore, there is a need for more large-scale clinical studies evaluating treatment options for POD, with a focus on the impacts of antibiotic resistance and its implications on public health.
CITATION: Swenson K, Graber E. A single-center pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis. J Drugs Dermatol. 2025;24(6):617-620. doi:10.36849/JDD.8590.
OBJECTIVE: The main objective of this study is to demonstrate sarecycline’s efficacy and safety in treating POD. It was hypothesized that subjects with POD given a 4-week course of sarecycline would have improvement in their POD and tolerate the medication well.
METHODS: This was a single-center, prospective, pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for the treatment of POD with once-daily dosing over 4 consecutive weeks. Subjects were evaluated using the PODSI score at weeks 0, 2, and 4.
RESULTS: All 9 subjects who completed the study had shown improvement in POD with no reported drug-related adverse events. All subjects were female, and the mean age was 41 years old.
CONCLUSION: Sarecycline may be an appropriate novel treatment option for POD and should be explored further in a larger population study capturing this data. Furthermore, there is a need for more large-scale clinical studies evaluating treatment options for POD, with a focus on the impacts of antibiotic resistance and its implications on public health.
CITATION: Swenson K, Graber E. A single-center pilot study to evaluate the efficacy, safety, and tolerability of sarecycline for treating periorificial dermatitis. J Drugs Dermatol. 2025;24(6):617-620. doi:10.36849/JDD.8590.